<SEC-DOCUMENT>0001192482-19-000432.txt : 20191113
<SEC-HEADER>0001192482-19-000432.hdr.sgml : 20191113
<ACCEPTANCE-DATETIME>20191113210616
ACCESSION NUMBER:		0001192482-19-000432
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20191113
FILED AS OF DATE:		20191113
DATE AS OF CHANGE:		20191113

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Ellis Ronald J. Jr.
		CENTRAL INDEX KEY:			0001790670

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39130
		FILM NUMBER:		191216023

	MAIL ADDRESS:	
		STREET 1:		C/O TELA BIO, INC.
		STREET 2:		1 GREAT VALLEY PARKWAY, SUITE 24
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Pacira BioSciences, Inc.
		CENTRAL INDEX KEY:			0001396814
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39130
		FILM NUMBER:		191216024

	BUSINESS ADDRESS:	
		STREET 1:		5 SYLVAN WAY
		STREET 2:		SUITE 300
		CITY:			PARSIPPANY
		STATE:			NJ
		ZIP:			07054
		BUSINESS PHONE:		973-254-3560

	MAIL ADDRESS:	
		STREET 1:		5 SYLVAN WAY
		STREET 2:		SUITE 300
		CITY:			PARSIPPANY
		STATE:			NJ
		ZIP:			07054

	FORMER NAME:	
		FORMER CONFORMED NAME:	Pacira Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20101029

	FORMER NAME:	
		FORMER CONFORMED NAME:	PACIRA INC
		DATE OF NAME CHANGE:	20080318

	FORMER NAME:	
		FORMER CONFORMED NAME:	Blue Acquisition Corp
		DATE OF NAME CHANGE:	20070418

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TELA Bio, Inc.
		CENTRAL INDEX KEY:			0001561921
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				455320061
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		1 GREAT VALLEY PARKWAY, SUITE 24
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		484-320-2930

	MAIL ADDRESS:	
		STREET 1:		1 GREAT VALLEY PARKWAY, SUITE 24
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>edgar.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2019-11-13</periodOfReport>

    <issuer>
        <issuerCik>0001561921</issuerCik>
        <issuerName>TELA Bio, Inc.</issuerName>
        <issuerTradingSymbol>TELA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001790670</rptOwnerCik>
            <rptOwnerName>Ellis Ronald J. Jr.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PACIRA BIOSCIENCES, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>5 SYLVAN WAY, SUITE 300</rptOwnerStreet2>
            <rptOwnerCity>PARSIPPANY</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07054</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001396814</rptOwnerCik>
            <rptOwnerName>Pacira BioSciences, Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>5 SYLVAN WAY, SUITE 300</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>PARSIPPANY</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07054</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2019-11-13</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>C</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>580357</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>774056</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Pacira BioSciences, Inc.</value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Series B Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2019-11-13</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>C</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>14329052</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>580357</value>
                    <footnoteId id="F3"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Pacira BioSciences, Inc.</value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.</footnote>
        <footnote id="F2">Reflects 193,699 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a).</footnote>
        <footnote id="F3">Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Nora Brennan as attorney-in-fact for Ronald J. Ellis, Jr.</signatureName>
        <signatureDate>2019-11-13</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
